A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Publication | Closed Access

DOI

Citations

References

2014

Year

Yoshihiro Hattori, Miyako Satouchi, Temiko Shimada, Yoshiko Urata, Tsutomu Yoneda, Masahide Mori, Takashi Nishimura, Hironobu Sunadome, Toru Kumagai, Fumio Imamura,

Lung Cancer

MedicinePathologyBronchial NeoplasmImmune Checkpoint InhibitorCancer TreatmentPhase 2OncologyRadiation OncologyLung CancerMolecular Oncology